Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company specializing in immunotherapies, announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. Steven Kelly, President and CEO, will engage in a fireside chat on December 5th at 9:35 am ET. The event will be accessible via audio webcast on the company's Investor Relations webpage under the Investor Events section, with -time archive availability.
Carisma Therapeutics (Nasdaq: CARM), una compagnia biofarmaceutica in fase clinica specializzata in immunoterapie, ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore ISI HealthCONx. Steven Kelly, Presidente e CEO, parteciperà a una conversazione informale il 5 dicembre alle 9:35 ora ET. L'evento sarà accessibile tramite audiowebcast sulla pagina delle Relazioni con gli Investitori della compagnia, nella sezione Eventi per Investitori, con disponibilità di archiviazione nel tempo.
Carisma Therapeutics (Nasdaq: CARM), una empresa biofarmacéutica en etapa clínica especializada en inmunoterapias, anunció su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx. Steven Kelly, Presidente y CEO, participará en una charla informal el 5 de diciembre a las 9:35 am ET. El evento será accesible a través de una transmisión de audio en la página de Relaciones con Inversores de la compañía, en la sección de Eventos para Inversores, con disponibilidad de archivo a lo largo del tiempo.
Carisma Therapeutics (Nasdaq: CARM), 면역 치료제를 전문으로 하는 임상 단계의 생명공학 회사가 제7회 연례 Evercore ISI HealthCONx 컨퍼런스에 참석한다고 발표했습니다. Steven Kelly 사장 겸 CEO는 12월 5일 오전 9:35 ET에 파이어사이드 채팅에 참여할 예정입니다. 이 이벤트는 회사의 투자자 관계 웹페이지의 투자자 이벤트 섹션을 통해 오디오 웹캐스트로 접근할 수 있으며, 실시간 아카이브도 제공됩니다.
Carisma Therapeutics (Nasdaq: CARM), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les immunothérapies, a annoncé sa participation à la 7ème Conférence Annuelle Evercore ISI HealthCONx. Steven Kelly, Président et CEO, participera à une discussion au coin du feu le 5 décembre à 9h35 ET. L'événement sera accessible via un webinaire audio sur la page des Relations Investisseurs de l'entreprise, dans la section Événements pour Investisseurs, avec une disponibilité d'archive au fil du temps.
Carisma Therapeutics (Nasdaq: CARM), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Immuntherapien spezialisiert hat, gab seine Teilnahme an der 7. jährlichen Evercore ISI HealthCONx-Konferenz bekannt. Steven Kelly, Präsident und CEO, wird am 5. Dezember um 9:35 Uhr ET an einem Fireside-Chat teilnehmen. Die Veranstaltung wird über einen Audio-Webcast auf der Investor-Relations-Webseite des Unternehmens im Abschnitt Investor-Events zugänglich sein, mit Archivverfügbarkeit über die Zeit.
- None.
- None.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-302316979.html
SOURCE Carisma Therapeutics Inc.
FAQ
When is Carisma Therapeutics (CARM) presenting at the Evercore ISI HealthCONx Conference 2024?
How can investors watch Carisma Therapeutics' (CARM) presentation at the HealthCONx Conference?
Who will represent Carisma Therapeutics (CARM) at the 2024 Evercore ISI HealthCONx Conference?
What type of presentation will Carisma Therapeutics (CARM) give at the HealthCONx Conference?
